EPS for Fresenius Medical Care AG & Co. KGaA (FMS) Expected At $0.70

April 27, 2018 - By Nellie Frank

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Logo

Analysts expect Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to report $0.70 EPS on May, 3 after the close.They anticipate $0.17 EPS change or 32.08 % from last quarter’s $0.53 EPS. FMS’s profit would be $431.97 million giving it 17.98 P/E if the $0.70 EPS is correct. After having $0.69 EPS previously, Fresenius Medical Care AG & Co. KGaA’s analysts see 1.45 % EPS growth. The stock increased 1.66% or $0.82 during the last trading session, reaching $50.34. About 284,554 shares traded or 73.96% up from the average. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has risen 18.90% since April 27, 2017 and is uptrending. It has outperformed by 7.35% the S&P500.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

Among 4 analysts covering Fresenius Medical Care Corp (NYSE:FMS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Fresenius Medical Care Corp had 5 analyst reports since November 2, 2017 according to SRatingsIntel. The company was upgraded on Tuesday, April 24 by Deutsche Bank. The rating was maintained by SunTrust on Thursday, November 2 with “Buy”. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Monday, December 11 report. As per Wednesday, December 20, the company rating was maintained by SunTrust. The firm earned “Hold” rating on Thursday, November 2 by RBC Capital Markets.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. The company has market cap of $31.07 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. It has a 19.68 P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.